THE SELECTIVE ALPHA-BLOCKER ALFUZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

40 patients with benign prostatic hyperplasia (BPH) were treated with the alpha-blocker alfuzosin which was administered per os twice a day in a dose 5 mg. The treatment brought about a decrease of the mean sym ptom score from 19.6 to 12.2, of quality of life from 5.2 to 2.1, of r esidual urine from 152 to 82 ml. Mean and maximal urinary flow rates r ose by 35 and 45%, respectively. The level of prostate-specific antige n over the treatment course did not change. The findings of the trial evidence for high efficacy of alfuzosin in the treatment of urination disorders in BPH patients.